MAPK3 and Cognitive impairment: On the basis of our findings, Ito et al. [17] and Mizoguchi et al. [21] showed that ZSET1446, a novel azaindolizine derivative, or minocycline ameliorated METH-induced cognitive impairment through, at least in part, activation of the ERK1/2 pathway in the PFC linked to dopamine D1 receptors.